Is Standard BioTools Inc. (LAB) a Buy, Sell, or Hold?
NASDAQ : LAB
Standard BioTools Inc.
$0.8332 USD
-$0.04 (-4.81%)
- Volume
- 994.43K
- Average Volume
- 3.54M
- Market Capitalization
- $326.17M
- P/E Ratio
- -3.33
- Dividend Yield
- 0.00%
- Price Target
- $3.25
- Year High
- $1.72
- Year Low
- $0.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.36
Company Overview
NASDAQ
Michael Egholm
Medical - Equipment & Services
Healthcare
LAB
389
US
USD
Liquidity Metrics
0.05
12.36
11.92
6.30
0.00
Sales & Valuation
$85.33M
3.78
0.58
-3.45
-0.24
Profitability
-$0.2
-$74.9M
-109.08%
-101.82%
-20.80%
-14.72%
P/E Metrics
-3.33
-0.43
-0.43
Analyst Price Target & Rating
$3.25
$3.25
$3.25
2/5
10 Analysts
-74.36%
Financial Health Scores
0.61
2/9
$479.25M
$639.11M
$77.99M
-$87.8M
Key Metrics (TTM)
$89.89M
1.04
-1.10
12.36
-20.80%
-7.43%
-29.09%
-28.97%
157 days
Company Executives
| Name | Title |
|---|---|
| Sean Mackay | Chief Business Officer & Senior Vice President |
| Anders Davas | Senior Vice President of Global Operations |
| Hanjoon Kim | Chief Financial Officer |
| Elizabeth R. Jensen | Chief Human Resources Officer |
| Jonathan Mickelsen | Vice President & Chief Accounting Officer |
| Michael Egholm | President, Chief Executive Officer & Director |
| Mike Musgnug | Senior Vice President & Chief Commercial Officer |
| John Graziano | Vice President of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Standard BioTools Inc. (NASDAQ:LAB) Stock
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; ... Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 07:00:00
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
2026-07-21 15:00:00
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
2026-07-21 14:53:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-07-20 07:30:00
Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts
2026-06-19 12:48:57
BALA CYNWYD, Pa. , June 19, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
2026-06-17 08:30:00
SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?
2026-06-15 13:29:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-06-15 11:00:00
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing
Frequently Asked Questions
-
What is the current Standard BioTools Inc. (LAB) stock price?
-
Standard BioTools Inc.(NASDAQ:LAB) stock price is $0.8332 in the last trading session. During the trading session, LAB stock reached the peak price of $1.72 while $0.7 was the lowest point it dropped to. The percentage change in LAB stock occurred in the recent session was --4.81% while the dollar amount for the price change in LAB stock was -$0.04.
-
LAB's industry and sector of operation?
-
The NASDAQ listed LAB is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector.
-
Who are the executives of LAB?
-
Sean Mackay | Chief Business Officer & Senior Vice President
Anders Davas | Senior Vice President of Global Operations
Hanjoon Kim | Chief Financial Officer
Elizabeth R. Jensen | Chief Human Resources Officer
Jonathan Mickelsen | Vice President & Chief Accounting Officer -
How many employees does LAB have?
-
Number of LAB employees currently stands at 389. LAB operates from 50 Milk Street, Boston, MA 02109, US.
-
Link for LAB official website?
-
Official Website of LAB is: https://www.standardbio.com
-
How do I contact LAB?
-
LAB could be contacted at phone #650 266 6000 and can also be accessed through its website. LAB operates from 50 Milk Street, Boston, MA 02109, US.
-
How many shares of LAB are traded daily?
-
The average number of LAB shares traded daily for last 3 months was 3.54M.
-
What is the market cap of LAB currently?
-
The market value of LAB currently stands at $326.17M with its latest stock price at $0.8332